PKX-001

Drug Profile

PKX-001

Alternative Names: AAGP; PKX 001

Latest Information Update: 31 Mar 2017

Price : $50

At a glance

  • Originator Institut National des Sciences Appliquees de Rouen; ProtoKinetix
  • Developer ProtoKinetix; University of Alberta
  • Class Glycopeptides; Glycoproteins; Small molecules
  • Mechanism of Action Antioxidants; Free radical scavengers; Selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Type 1 diabetes mellitus

Most Recent Events

  • 16 Feb 2017 Phase-I/II clinical trials in Type-1 diabetes mellitus in Canada (unspecified route) (NCT03073577)
  • 17 Jan 2017 University of Alberta submits Investigational Testing Authorization (ITA) to Health Canada for Type-1 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top